Supercharged immune cells take on incurable tumors
NCT ID NCT04520711
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial tests a new approach for people with advanced epithelial cancers that cannot be cured. Researchers take a patient's own immune cells, genetically engineer them to recognize unique cancer markers, and infuse them back along with two drugs that boost the immune response. The main goal is to check safety in 24 participants, with early signs of tumor shrinkage also tracked.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Engineered immune cells (TCR-T) plus two immune-boosting drugs (CDX-1140 and pembrolizumab)
What this could lead to
If it works, this could point toward a new treatment option for people with advanced cancers that currently have no cure.
What could go wrong
This is a very early (phase I) safety study with only 24 participants. The treatment may not shrink tumors, and side effects could be serious.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MALIGNANT EPITHELIAL NEOPLASMS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Providence Portland Medical Center
Portland, Oregon, 97213, United States